HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity

Nature Neuroscience

Volumn 15, Issue 9, 2012, Pages 1245-1254

  Kurita, Mitsumasa ^a   Holloway, Terrell ^a   Garcà A Bea, Aintzane ^a,b,c   Kozlenkov, Alexey ^a   Friedman, Allyson K ^a   Moreno, José L ^a   Heshmati, Mitra ^a   Golden, Sam A ^a   Kennedy, Pamela J ^a   Takahashi, Nagahide ^a   Dietz, David M ^a   Mocci, Giuseppe ^a   Gabilondo, Ane M ^b,c   Hanks, James ^a   Umali, Adrienne ^a   Callado, Luis F ^b,c   Gallitano, Amelia L ^d   Neve, Rachael L ^e   Shen, Li ^a   Buxbaum, Joseph D ^a   Han, Ming Hu ^a   Nestler, Eric J ^a   Meana, J Javier ^b,c   Russo, Scott J ^a   González Maeso, Javier ^a   more..

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; ENTINOSTAT; FLUOXETINE; HALOPERIDOL; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 4; HYDROLASE INHIBITOR; METABOTROPIC RECEPTOR 2; RISPERIDONE; SEROTONIN 2A RECEPTOR; TRICHOSTATIN A; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA MODIFICATION; DOWN REGULATION; ELECTROPHYSIOLOGY; EPIGENETICS; FRONTAL CORTEX; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PSYCHOSIS; SCHIZOPHRENIA; SINGLE DRUG DOSE; UPREGULATION;

ACETYLATION; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZAMIDES; CHROMATIN IMMUNOPRECIPITATION; CLOZAPINE; DNA METHYLATION; GENETIC VECTORS; HEK293 CELLS; HERPESVIRUS 2, HUMAN; HISTONE DEACETYLASE 2; HISTONES; HUMANS; HYDROXAMIC ACIDS; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; PATCH-CLAMP TECHNIQUES; PLASMIDS; PREFRONTAL CORTEX; PROMOTER REGIONS, GENETIC; PYRIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIC PSYCHOLOGY; STARTLE REACTION;

EID: 84866141733     PISSN: 10976256     EISSN: 15461726     Source Type: Journal    
DOI: 10.1038/nn.3181     Document Type: Article

References (60)

1. Sawa, A. & Snyder, S.H. Schizophrenia: diverse approaches to a complex disease. Science 296, 692-695 (2002).
2. Dobbs, D. Schizophrenia: the making of a troubled mind. Nature 468, 154-156 (2010).
3. Lieberman, J.A. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209-1223 (2005).
4. Lieberman, J.A. et al. Antipsychotic drugs: comparison in animal models of effcacy, neurotransmitter regulation, and neuroprotection. Pharmacol. Rev. 60, 358-403 (2008).
5. Van Sant, S.P. & Buckley, P.F. Pharmacotherapy for treatment-refractory schizophrenia. Expert Opin. Pharmacother. 12, 411-434 (2011).
6. Dong, E., Guidotti, A., Grayson, D.R. & Costa, E. Histone hyperacetylation induces demethylation of reelin and 67-kDa glutamic acid decarboxylase promoters. Proc. Natl. Acad. Sci. USA 104, 4676-4681 (2007).
7. Dong, E., Nelson, M., Grayson, D.R., Costa, E. & Guidotti, A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc. Natl. Acad. Sci. USA 105, 13614-13619 (2008).
8. Abel, T. & Zukin, R.S. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr. Opin. Pharmacol. 8, 57-64 (2008).
9. Citrome, L. et al. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatr. Serv. 55, 290-294 (2004).
10. Kelly, D.L. et al. Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. Psychiatr. Q. 77, 81-95 (2006).
11. Suzuki, T. et al. Augmentation of atypical antipsychotics with valproic acid. An open-label study for most diffcult patients with schizophrenia. Hum. Psychopharmacol. 24, 628-638 (2009).
12. Löscher, W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog. Neurobiol. 58, 31-59 (1999).
13. Gurvich, N., Tsygankova, O.M., Meinkoth, J.L. & Klein, P.S. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res. 64, 1079-1086 (2004).
14. Borrelli, E., Nestler, E.J., Allis, C.D. & Sassone-Corsi, P. Decoding the epigenetic language of neuronal plasticity. Neuron 60, 961-974 (2008).
15. Arrowsmith, C.H., Bountra, C., Fish, P.V., Lee, K. & Schapira, M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11, 384-400 (2012).
16. Miyamoto, S., Duncan, G.E., Marx, C.E. & Lieberman, J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10, 79-104 (2005).
17. González-Maeso, J. & Sealfon, S.C. Psychedelics and schizophrenia. Trends Neurosci. 32, 225-232 (2009).
18. Vollenweider, F.X., Vollenweider-Scherpenhuyzen, M.F., Babler, A., Vogel, H. & Hell, D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9, 3897-3902 (1998).
19. González-Maeso, J. et al. Hallucinogens recruit specifc cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53, 439-452 (2007).
20. Moreno, J.L., Sealfon, S.C. & González-Maeso, J. Group II metabotropic glutamate receptors and schizophrenia. Cell. Mol. Life Sci. 66, 3777-3785 (2009).
21. Fell, M.J., Svensson, K.A., Johnson, B.G. & Schoepp, D.D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J. Pharmacol. Exp. Ther. 326, 209-217 (2008).
22. Woolley, M.L., Pemberton, D.J., Bate, S., Corti, C. & Jones, D.N. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl.) 196, 431-440 (2008).
23. Fribourg, M. et al. Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 147, 1011-1023 (2011).
24. Patil, S.T. et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 13, 1102-1107 (2007).
25. González-Maeso, J. et al. Identifcation of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452, 93-97 (2008).
26. Agid, O., Kapur, S., Arenovich, T. & Zipursky, R.B. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch. Gen. Psychiatry 60, 1228-1235 (2003).
27. Egan, M.F. et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc. Natl. Acad. Sci. USA 101, 12604-12609 (2004).
28. Liu, W. et al. Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia. Pharmacogenomics J. 12, 246-254 (2012).
29. Moreno, J.L. et al. Maternal infuenza viral infection causes schizophrenia-like alterations of 5-HT2A and mGlu2 receptors in the adult offspring. J. Neurosci. 31, 1863-1872 (2011).
30. Abdolmaleky, H.M. et al. Epigenetic dysregulation of HTR2A in the brain of patients with schizophrenia and bipolar disorder. Schizophr. Res. 129, 183-190 (2011).
31. Matrisciano, F., Tueting, P., Maccari, S., Nicoletti, F. & Guidotti, A. Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice. Neuropsychopharmacology 37, 929-938 (2012).
32. Huang, H.S., Matevossian, A., Jiang, Y. & Akbarian, S. Chromatin immunoprecipitation in postmortem brain. J. Neurosci. Methods 156, 284-292 (2006).
33. Darcy, M.J., Calvin, K., Cavnar, K. & Ouimet, C.C. Regional and subcellular distribution of HDAC4 in mouse brain. J. Comp. Neurol. 518, 722-740 (2010).
34. González-Maeso, J. et al. Transcriptome fngerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J. Neurosci. 23, 8836-8843 (2003).
35. Tamaru, Y., Nomura, S., Mizuno, N. & Shigemoto, R. Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre-and postsynaptic sites. Neuroscience 106, 481-503 (2001).
36. Benneyworth, M.A. et al. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol. Pharmacol. 72, 477-484 (2007).
37. Aghajanian, G.K. Modeling "psychosis" in vitro by inducing disordered neuronal network activity in cortical brain slices. Psychopharmacology (Berl.) 206, 575-585 (2009).
38. Zhai, Y. et al. Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex. Neuropsychopharmacology 28, 45-52 (2003).
39. Kristiansen, L.V., Huerta, I., Beneyto, M. & Meador-Woodruff, J.H. NMDA receptors and schizophrenia. Curr. Opin. Pharmacol. 7, 48-55 (2007).
40. Nestler, E.J. & Hyman, S.E. Animal models of neuropsychiatric disorders. Nat. Neurosci. 13, 1161-1169 (2010).
41. Geyer, M.A. & Vollenweider, F.X. Serotonin research: contributions to understanding psychoses. Trends Pharmacol. Sci. 29, 445-453 (2008).
42. Ludewig, K., Geyer, M.A. & Vollenweider, F.X. Defcits in prepulse inhibition and habituation in never-medicated, frst-episode schizophrenia. Biol. Psychiatry 54, 121-128 (2003).
43. Chiechio, S. et al. Epigenetic modulation of mGlu2 receptors by histone deacetylase inhibitors in the treatment of infammatory pain. Mol. Pharmacol. 75, 1014-1020 (2009).
44. Tsankova, N., Renthal, W., Kumar, A. & Nestler, E.J. Epigenetic regulation in psychiatric disorders. Nat. Rev. Neurosci. 8, 355-367 (2007).
45. Guan, J.S. et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459, 55-60 (2009).
46. Gräff, J. et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 483, 222-226 (2012).
47. Peter, C.J. & Akbarian, S. Balancing histone methylation activities in psychiatric disorders. Trends Mol. Med. 17, 372-379 (2011).
48. Marder, E. & Taylor, A.L. Multiple models to capture the variability in biological neurons and networks. Nat. Neurosci. 14, 133-138 (2011).
49. Dean, B. The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice. J. Neurochem. 85, 1-13 (2003).
50. Goldberg, T.E. et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br. J. Psychiatry 162, 43-48 (1993).
51. Tsankova, N.M. et al. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat. Neurosci. 9, 519-525 (2006).
52. Humphrey, G.W. et al. Complementary roles for histone deacetylases 1, 2, and 3 in differentiation of pluripotent stem cells. Differentiation 76, 348-356 (2008).
53. Deacon, R.M. & Rawlins, J.N. T-maze alternation in the rodent. Nat. Protoc. 1, 7-12 (2006).
54. Hof, P.R., Young, W.G., Bloom, F.E., Belichenko, P.V. & Celio, M.R. Comparative Cytoarchitectonic Atlas of the C57BL/6 and 129/Sv Mouse Brains (Elsevier, Amsterdam, 2000).
55. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV 4th edn. (Washington, DC, 1994).
56. Stan, A.D. et al. Human postmortem tissue: what quality markers matter? Brain Res. 1123, 1-11 (2006).
57. Cao, J.L. et al. Mesolimbic dopamine neurons in the brain reward circuit mediate susceptibility to social defeat and antidepressant action. J. Neurosci. 30, 16453-16458 (2010).
58. Martin, W.R., Wikler, A., Eades, C.G. & Pescor, F.T. Tolerance to and physical dependence on morphine in rats. Psychopharmacologia 4, 247-260 (1963).
59. González-Maeso, J., Rodriguez-Puertas, R., Meana, J.J., Garcia-Sevilla, J.A. & Guimon, J. Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: selective supersensitivity of alpha(2A)-adrenoceptors. Mol. Psychiatry 7, 755-767 (2002).
60. Shaffer, J.P. Multiple hypothesis testing. Annu. Rev. Psychol. 46, 561-584 (1995).